Abstract:Zhaohong Wang, 1, 2, * Hui Chen, 1, * Jingjing Chen, 1, * Zhong Hong, 1 Yi Liao, 1 Qiyu Zhang, 1, 2 Hongfei Tong 1 1 Department of Hepatobiliary Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325000, People's Republic of China; 2 Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, People's Republic of China *These authors contributed equally to this work Correspondence: Qiyu Zhang; Hongfei Tong Department of Hepatobiliary Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 Xueyuan W Road, Lucheng Qu, Wenzhou Shi, Zhejiang Sheng 32500, People's Republic of China Tel +86 5 778 800 2710; +86 5 778 800 2710 Email qiyuz@126.com; tonghongfei@163.com Background: Excessive expression of EGFR is closely related to tumor formation, transfer and deterioration, which has attracted much attention. EGFR overexpression may be detected in up to 90% of pancreatic tumors. However, drug resistance of EGFR inhibitors targeting treatment severely limits its clinical application. Methods: In this study, Western blotting was used to detect the expression of p-Stat3, EGFR, Bcl-2, cleaved-caspase3 and Bax. Cell apoptosis was evaluated via flow cytometry. The colon assay and MTT assay were applied for detecting the cell proliferation in vitro. The xenograft mouse model was used to examine the cell proliferation in vivo. Results: Emodin remarkably enhanced the anti-cancer effect of EGFR inhibitor on pancreatic cancer cells. In addition, emodin promoted afatinib-induced apoptosis by inhibiting the Stat3 signaling pathway. Meanwhile, siRNAs against Stat3 significantly increased the apoptosis of pancreatic cancer cells. EGFR inhibitor promoted phosphorylation of Stat3 in pancreatic cancer cells. Interestingly, emodin combined with EGFR inhibitor inhibited the proliferation of pancreatic cancer cells in vitro. The tumor xenograft mice model was further confirmed that emodin possessed a synergy anticancer effect with afatinib on pancreatic cancer cells by regulating the Stat3 expression. Conclusion: These results indicate that the combination of emodin with EGFR inhibitor is an effective therapeutic strategy to sensitize human pancreatic cancer. Keywords: pancreatic cancer, EGFR inhibitors, afatinib, Stat3

Alantolactone sensitizes human pancreatic cancer cells to EGFR inhibitors through the inhibition of STAT3 signaling

Alantolactone Induces Apoptosis and Improves Chemosensitivity of Pancreatic Cancer Cells by Impairment of Autophagy-Lysosome Pathway Via Targeting TFEB

Alantolactone enhances the sensitivity of melanoma to MAPK pathway inhibitors by targeting inhibition of STAT3 activation and down-regulating stem cell markers

Alantolactone Induces Apoptosis and Cell Cycle Arrest on Lung Squamous Cancer Sk-Mes-1 Cells

Alantolactone Enhances Gemcitabine Sensitivity of Lung Cancer Cells Through the Reactive Oxygen Species-Mediated Endoplasmic Reticulum Stress and Akt/GSK3β Pathway

Natural Product Alantolactone Targeting AKR1C1 Suppresses Cell Proliferation and Metastasis in Non-Small-Cell Lung Cancer

Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment

Anti-EGFR therapeutic efficacy correlates directly with inhibition of STAT3 activity

Alantolactone, a Sesquiterpene Lactone, Inhibits Breast Cancer Growth by Antiangiogenic Activity Via Blocking VEGFR2 Signaling.

Telocinobufagin Has Antitumor Effects in Non-Small-Cell Lung Cancer by Inhibiting STAT3 Signaling

Synergistic antitumor activity of baicalein combined with almonertinib in almonertinib-resistant non-small cell lung cancer cells through the reactive oxygen species-mediated PI3K/Akt pathway

Apoptosis induction by alantolactone in breast cancer MDA-MB-231 cells through reactive oxygen species-mediated mitochondrion-dependent pathway

Cyclosporine A Sensitizes Human Non-Small Cell Lung Cancer Cells to Gefitinib Through Inhibition of STAT3.

Isoalantolactone Inhibits Esophageal Squamous Cell Carcinoma Growth Through Downregulation of MicroRNA-21 and Derepression of PDCD4

Potent Inhibition of Gastric Cancer Cells by a Natural Compound Via Inhibiting TrxR1 Activity and Activating ROS-mediated P38 MAPK Pathway

Emodin sensitizes human pancreatic cancer cells to EGFR inhibitor through suppressing Stat3 signaling pathway

Role of chemokine-mediated angiogenesis in resistance towards crizotinib and its reversal by anlotinib in EML4-ALK positive NSCLC

A Novel Ageladine A Derivative Acts as a STAT3 Inhibitor and Exhibits Potential Antitumor Effects

L-Theanine Inhibits Chemoresistance of Lung Cancer Cells to Cisplatin by Regulating STAT3/NOTCH1-BMAL1 Signaling

Mitochondrial impairment and downregulation of Drp1 phosphorylation underlie the antiproliferative and proapoptotic effects of alantolactone on oral squamous cell carcinoma cells

Alantolactone induces apoptosis in chronic myelogenous leukemia sensitive or resistant to imatinib through NF-κB inhibition and Bcr/Abl protein deletion